The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Albert Einstein College of Medicine enters agreement with Jiangsu Hengrui Medicine

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

ALBERT EINSTEIN COLLEGE OF MEDICINE entered into a research agreement with Jiangsu Hengrui Medicine Co. Ltd. to develop innovative cancer therapies. The collaboration is the first between Einstein and a pharmaceutical company based in China.

Jiangsu Hengrui Medicine, established in 1970, is a fully integrated pharmaceutical company with annual net sales of over $1.2 billion. Hengrui’s products and research span therapeutic areas including oncology and hematology, anesthesiology and pain management, cardiovascular and metabolic diseases, contrast media and inflammation.

Table of Contents

YOU MAY BE INTERESTED IN

Guest Editorial

USPSTF doesn’t lean right or left—it’s about data, not politics

Multiple components of the healthcare and public health systems are currently under scrutiny. One of them is reportedly the U.S. Preventive Services Task Force (USPSTF: “Task Force”), established in 1984 and managed by the Agency for Healthcare Research and Quality.  It was created to maintain an ongoing evaluation of disease prevention and screening interventions that...

By Barnett Kramer
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account